Stephanie Tozzo
Directeur Technique/Scientifique/R&D chez Avilar Therapeutics, Inc.
Fortune : - $ au 31/05/2024
Profil
Stephanie Tozzo currently works at Avilar Therapeutics, Inc., as Chief Science Officer & Senior Vice President from 2021.
Dr. Tozzo also formerly worked at CohBar, Inc., as Director from 2022 to 2023.
Dr. Tozzo received her graduate degree from Université Paris-Saclay.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
COHBAR INC
-.--% | 15/08/2023 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Stephanie Tozzo
| Sociétés | Poste | Début |
|---|---|---|
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Directeur Technique/Scientifique/R&D | 01/11/2021 |
Anciens postes connus de Stephanie Tozzo
| Sociétés | Poste | Fin |
|---|---|---|
| COHBAR, INC. | Directeur/Membre du Conseil | 10/11/2023 |
Formation de Stephanie Tozzo
| Université Paris-Saclay | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COHBAR, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
